18F-FDG PET/CT-based metabolic metrics in recurrent tumors of ovarian clear cell carcinoma and their prognostic implications

Table 3 Recurrence pattern of patients with early-stage disease at first diagnosis (n = 13)

No	Age	Stage	PFS (Months)	Platinum response	CA125 (U/mL)	Relapsed tumor	SUVmax	Second-line treatment	Status at last follow-up	PRS (Months)	OS (Months)
1	51	II	24	Sensitive	52.56	Vaginal cuff	(−)^a	SCS + Chemo	Alive	126	150
2	47	I	48	Sensitive	3.90	Vaginal cuff	(−)^a	SCS + Chemo	Alive	94	142
3	53	II	13	Sensitive	10.50	Pelvic tumor	7.2	SCS + Chemo	Dead	29	42
4	54	I	19	Sensitive	4.9	Lung	3.4	SCS + Chemo	Alive	95	114
5	54	I	31	Sensitive	48.60	Multiple lymph nodes	4.7	SCS + Chemo	Dead	43	74
6	53	II	6	Resistant	11.24	Abdominal wall tumor, liver, rectal tumor	13.4	SCS + Chemo	Dead	6	12
7	59	I	20	Sensitive	21.63	Multiple lymph nodes	7.9	SCS + Chemo	Dead	10	30
8	60	I	108	Sensitive	115.30	Supra-diaphragmatic lymph node, Intestinal mesentery, pelvic tumor, vaginal cuff	14.3	SCS + Chemo	Alive	36	144
9	36	I	34	Sensitive	8.31	Spleen	5.4	SCS + Chemo	Dead	24	58
10	46	I	9	Resistant	23.74	Abdominal wall tumor	9.0	SCS + Chemo	Alive	18	27
11	62	I	6	Resistant	40.65	Pelvic tumor	4.9	SCS + Chemo	Alive	13	19
12	34	II	34	Sensitive	154.30	Multiple lymph nodes, peritoneum, liver	20.6	Chemo	Alive	15	49
13	48	I	13	Sensitive	32.21	Pelvic tumor	5.0	SCS	Unknown^b	Unknown^b	Unknown^b

^aTwo patients presented with low glucose-uptake tumor
^bThis patient lost follow up after second cytoreduction surgery in our hospital
Abbreviations: PFS Progression Free Survival, SUVmax Maximum Standardized Uptake Value, PRS Post-Relapse Survival, OS Overall Survival, SCS Secondary Cytoreduction Surgery, Chemo Chemotherapy

ISSN: 1471-2407